medRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 16, 2024
Abstract
The
role
of
molecular
traits
(e.g.,
gene
expression
and
protein
abundance)
in
the
occurrence,
development,
prognosis
lung
cancer
has
been
extensively
studied.
However,
biomarkers
other
layers
connections
among
various
that
influence
risk
remain
largely
underexplored.
We
conducted
first
comprehensive
assessment
associations
between
(i.e.,
DNA
methylation,
expression,
metabolite)
through
epigenome-wide
association
study
(EWAS),
transcriptome-wide
(TWAS),
proteome-wide
(PWAS)
metabolome-wide
(MWAS),
then
we
synthesized
all
omics
to
reveal
potential
regulatory
mechanisms
across
layers.
Our
analysis
identified
61
CpG
sites,
62
genes,
6
proteins,
5
metabolites,
yielding
123
novel
biomarkers.
These
highlighted
90
relevant
genes
for
cancer,
83
them
were
established
our
study.
Multi-omics
integrative
revealed
12
these
overlapped
layers,
suggesting
cross-omics
interactions.
Moreover,
106
cross-layer
pathways,
indicating
cell
proliferation,
differentiation,
immunity,
protein-catalyzed
metabolite
reaction
interact
risk.
Further
subgroup
analyses
biomarker
distributions
differ
patient
subgroups.
To
share
signals
different
with
community,
released
a
free
online
platform,
LungCancer-xWAS,
which
can
be
accessed
at
http://bigdata.njmu.edu.cn/LungCancer-xWAS/
.
findings
underscore
importance
xWAS
integrating
types
quantitative
trait
loci
(xQTL)
data
genome-wide
(GWAS)
deepen
understanding
pathophysiology,
may
provide
valuable
insights
into
therapeutic
targets
disease.
Human Genomics,
Journal Year:
2025,
Volume and Issue:
19(1)
Published: Jan. 31, 2025
Non-communicable
diseases
(NCDs)
such
as
cardiovascular
diseases,
chronic
respiratory
cancers,
diabetes,
and
mental
health
disorders
pose
a
significant
global
challenge,
accounting
for
the
majority
of
fatalities
disability-adjusted
life
years
worldwide.
These
arise
from
complex
interactions
between
genetic,
behavioral,
environmental
factors,
necessitating
thorough
understanding
these
dynamics
to
identify
effective
diagnostic
strategies
interventions.
Although
recent
advances
in
multi-omics
technologies
have
greatly
enhanced
our
ability
explore
interactions,
several
challenges
remain.
include
inherent
complexity
heterogeneity
multi-omic
datasets,
limitations
analytical
approaches,
severe
underrepresentation
non-European
genetic
ancestries
most
omics
which
restricts
generalizability
findings
exacerbates
disparities.
This
scoping
review
evaluates
landscape
data
related
NCDs
2000
2024,
focusing
on
advancements
integration,
translational
applications,
equity
considerations.
We
highlight
need
standardized
protocols,
harmonized
data-sharing
policies,
advanced
approaches
artificial
intelligence/machine
learning
integrate
study
gene-environment
interactions.
also
opportunities
translating
insights
(GxE)
research
into
precision
medicine
strategies.
underscore
potential
advancing
enhancing
patient
outcomes
across
diverse
underserved
populations,
emphasizing
fairness-centered
strategic
investments
build
local
capacities
underrepresented
populations
regions.
Nature,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 19, 2025
Depicting
spatial
distributions
of
disease-relevant
cells
is
crucial
for
understanding
disease
pathology1,2.
Here
we
present
genetically
informed
mapping
complex
traits
(gsMap),
a
method
that
integrates
transcriptomics
data
with
summary
statistics
from
genome-wide
association
studies
to
map
human
traits,
including
diseases,
in
spatially
resolved
manner.
Using
embryonic
datasets
covering
25
organs,
benchmarked
gsMap
through
simulation
and
by
corroborating
known
trait-associated
or
regions
various
organs.
Applying
brain
data,
reveal
the
distribution
glutamatergic
neurons
associated
schizophrenia
more
closely
resembles
cognitive
than
mood
such
as
depression.
The
schizophrenia-associated
were
distributed
near
dorsal
hippocampus,
upregulated
expression
calcium
signalling
regulation
genes,
whereas
depression-associated
deep
medial
prefrontal
cortex,
neuroplasticity
psychiatric
drug
target
genes.
Our
study
provides
demonstrates
gain
biological
insights
(such
trait-relevant
related
signature
genes)
these
maps.
Integration
enables
diseases
other
traits.
The Journal of Headache and Pain,
Journal Year:
2024,
Volume and Issue:
25(1)
Published: June 12, 2024
Currently,
the
treatment
and
prevention
of
migraine
remain
highly
challenging.
Mendelian
randomization
(MR)
has
been
widely
used
to
explore
novel
therapeutic
targets.
Therefore,
we
performed
a
systematic
druggable
genome-wide
MR
potential
targets
for
migraine.
The Annual Review of Pharmacology and Toxicology,
Journal Year:
2025,
Volume and Issue:
65(1), P. 131 - 148
Published: Jan. 23, 2025
Although
human
genetics
has
substantial
potential
to
illuminate
novel
disease
pathways
and
facilitate
drug
development,
identifying
causal
variants
deciphering
their
mechanisms
remain
challenging.
We
believe
these
challenges
can
be
addressed,
in
part,
by
creatively
repurposing
the
results
of
molecular
trait
genome-wide
association
studies
(GWASs).
In
this
review,
we
introduce
techniques
related
GWASs
unconventionally
apply
them
understanding
SVEP1,
a
coronary
artery
risk
locus.
Our
analyses
highlight
SVEP1's
link
cardiometabolic
glaucoma,
as
well
surprising
discovery
SVEP1
first
known
physiologic
ligand
for
PEAR1,
critical
receptor
governing
platelet
reactivity.
further
employ
dissect
interactions
between
Ang/Tie
pathway,
with
therapeutic
implications
constellation
diseases.
This
review
underscores
guide
unravel
complexities
health
demonstrating
an
integrative
approach
that
grounds
mechanistic
research
biology.
Scientific Reports,
Journal Year:
2025,
Volume and Issue:
15(1)
Published: March 8, 2025
The
integration
of
sequenced
samples
and
clinical
data
from
independent
yet
related
studies
public
domain
databases,
such
as
Sequence
Read
Archive
(SRA),
has
the
potential
to
increase
sample
sizes
enhance
statistical
power
needed
for
more
precise
bioinformatic
analysis.
Data
mining
grouping
are
starting
points
in
this
process
still
present
several
challenges,
including
presence
structured
unstructured
data,
missing
deposited
varying
experimental
conditions
techniques
applied
across
studies.
Designed
address
main
challenges
biomarkers
research,
proposed
methodology
employs
a
computational
approach
integrating
relational
database
construction,
text
mining,
natural
language
processing,
network
analysis,
search
by
Pubmed
publications,
combining
MeSH,
TTD
WordNet
identify
groups
with
same
characteristics.
As
result,
it
identifies
illustrates
relationships
among
collections,
aiming
discover
cancer
biomarkers.
In
colorectal
(CRC)
acute
lymphoblastic
leukemia
(ALL)
case
studies,
effectively
navigates
SRA
metadata,
retrieving,
extracting,
data.
It
highlights
significant
connections
between
patient
revealing
important
biological
insights.
study
grouped
2,737
3,655
into
comparison
groups,
demonstrating
method's
identifying
aiding
biomarker
discovery.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(17), P. 9371 - 9371
Published: Aug. 29, 2024
The
paradigm
“one
drug
fits
all”
or
dose
will
soon
be
challenged
by
pharmacogenetics
research
and
application.
Drug
response—efficacy
safety—depends
on
interindividual
variability.
current
clinical
practice
does
not
include
genetic
screening
as
a
routine
procedure
account
for
variation.
Patients
with
the
same
illness
receive
treatment,
yielding
different
responses.
Integrating
pharmacogenomics
in
therapy
would
provide
critical
information
about
how
patient
respond
to
certain
drug.
Worldwide,
great
efforts
are
being
made
achieve
personalized
therapy-based
approach.
Nevertheless,
global
harmonized
guideline
is
still
needed.
Plasma
membrane
proteins,
like
receptor
tyrosine
kinase
(RTK)
G
protein-coupled
receptors
(GPCRs),
ubiquitously
expressed,
involved
diverse
array
of
physiopathological
processes.
Over
30%
drugs
approved
FDA
target
GPCRs,
reflecting
importance
assessing
variability
among
individuals
who
treated
these
drugs.
Pharmacogenomics
transmembrane
protein
dynamic
field
profound
implications
precision
medicine.
Understanding
variations
provides
framework
optimizing
therapies,
minimizing
adverse
reactions,
advancing
healthcare.